EP1185281A1 - Combinaison de glucosamine avec des extraits d'herbes de tripterygium, ligustrum et erycibe - Google Patents

Combinaison de glucosamine avec des extraits d'herbes de tripterygium, ligustrum et erycibe

Info

Publication number
EP1185281A1
EP1185281A1 EP00937014A EP00937014A EP1185281A1 EP 1185281 A1 EP1185281 A1 EP 1185281A1 EP 00937014 A EP00937014 A EP 00937014A EP 00937014 A EP00937014 A EP 00937014A EP 1185281 A1 EP1185281 A1 EP 1185281A1
Authority
EP
European Patent Office
Prior art keywords
glucosamine
composition according
formulated
herbal composition
per
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00937014A
Other languages
German (de)
English (en)
Inventor
Shouming Zhong
Hongwen Yu
John G. Babish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Natural Products PLC
Original Assignee
Oxford Natural Products PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Natural Products PLC filed Critical Oxford Natural Products PLC
Publication of EP1185281A1 publication Critical patent/EP1185281A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/638—Ligustrum, e.g. Chinese privet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the present invention relates to herbal formulations comprising glucosamine and Chinese herbs which can be administered to humans and animals as dietary supplements and as pharmaceutical dosage forms to alleviate the symptoms of arthritis.
  • Glucosamine increases the ability of cartilage to synthesize both sulphated mucopolysaccharides and protein in a dose-dependent way, thus restoring the degradation- synthesis balance of cartilage.
  • Glucosamine increases the ability of cartilage to synthesize both sulphated mucopolysaccharides and protein in a dose-dependent way, thus restoring the degradation- synthesis balance of cartilage.
  • the symptoms of pain at rest- on standing, on exercise and during limited active and passive movements improved steadily through the treatment period. The improvement obtained lasted for a period of six to twelve weeks after the end of treatment.
  • Objective therapeutic efficacy was rated by the doctors as good in 59% of patients, and sufficient in an additional 36% of patients.
  • Oral glucosamine sulphate in the management of arthritis report on a multi-center open investigation in Portugal, 3 PHAlUviATj?ffiRAPET ⁇ cA.157-168 (1982). Oral glucosamine was fully tolerated by 86% of patients, a significantly larger proportion than that reported with other treatments and approached only by injectable glucosamine.
  • glucosamine is available in America and European countries as a dietary supplement in the form of tablets, capsules and chewable bars containing pharmaceutical grade glucosamine.
  • pure commercial glucosamine products are available containing glucosamine sulphate in 500 mg capsules or in 750 mg capsules.
  • Combinations of glucosamine with herbs, vitamins and minerals are also available; an example of a commercially available product contains glucosamine (300 mg), chondroitin sulfate, ginger, white willow, boswellia, curcumin, vitamin C, zinc, manganese, and selenium.
  • Other formulations of glucosamine include those described in U.S. Patent 5,679,344 to
  • glucosamine While glucosamine is generally accepted as being effective and safe for treating osteoarthritis, medical intervention into the treatment of this degenerative joint diseases is generally restricted to the alleviation of its acute symptoms.
  • Medical practitioners generally use nonsteroidal and steroidal anti-inflammatory drugs for treatment of osteoarthritis. These drugs, however, are not well-adapted for long-term therapy because they not only lack the ability to promote and protect cartilage, they can actually lead to degeneration of cartilage or reduction of its synthesis. Moreover, most nonsteroidal anti-inflammatory drugs damage the gastrointestinal system when used for extended periods of time. Thus, new treatments for arthritis are urgently needed.
  • glucosamine The joint-protective properties of glucosamine would make it an attractive therapeutic agent for arthritis except for two drawbacks: (i) the rate of response to glucosamine treatment is slower than for treatment with anti-inflammatory drugs, and (ii) glucosamine may fail to fulfill the expectation of degenerative remission.
  • studies comparing glucosamine with nonsteroidal anti-inflammatory agents for example, a double-blinded study comparing 1500 mg glucosamine sulfate per day with 1200 mg ibuprofen demonstrated that pain scores decreased faster during the first two weeks in the ibuprofen patients than in the glucosamine- treated patients.
  • glucosamine may relieve the pain and inflammation of arthritis at a slower rate than the available anti- inflammatory drugs.
  • An ideal formulation for the normalization of cartilage metabolism or treatment of osteoarthritis would combine adequate chondroprotection with potent anti-inflammatory activity.
  • the optimal formulation for arthritis should enhance the general joint rebuilding qualities offered by glucosamine and attenuate the inflammatory response without introducing any harmful side effects.
  • the formulation should be inexpensively manufactured and comply with all governmental regulations.
  • the present invention provides a herbal composition which comprises glucosamine and at least one herb selected from Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii.
  • Tripterygium wilfordii Ligustrum lucidum and Erycibe schmidtii are Chinese herbs that have been used for their anti-inflammatory properties.
  • Tripterygium wilfordii can be toxic when used in high amounts. It has surprisingly been found that, when incorporated into the herbal composition of the present invention, its anti-inflammatory effect is enhanced to the extent that it can be used at sufficiently low doses to avoid adverse side effects.
  • the herbal composition of the invention comprises glucosamine and each of Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii.
  • the herbal composition comprises synergistically effective amounts of the glucosamine and the or each said herb.
  • the invention therefore also provides the use of glucosamine as a synergist in a herbal composition which comprises at least one Chinese herb selected from Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii.
  • the invention further provides the use of at least one Chinese herb selected from Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii as a synergist in a herbal composition which comprises glucosamine.
  • the herbal composition preferably further comprises one or both of the other two said Chinese herbs.
  • the present invention also provides a pharmaceutical or veterinary composition that comprises a pharmaceutically or veterinarily effective amount of a herbal composition of the invention as defined above and a pharmaceutically or veterinarily acceptable carrier or diluent.
  • the invention further provides a dietary composition, such as a dietary supplement, which comprises a herbal composition of the invention as defined above and a dietetically acceptable carrier or diluent.
  • the present invention further provides a method of dietary supplementation which comprises the administration to a human or animal suffering symptoms of an ailment which involves the inflammation or degeneration of joint tissues, such as arthritis, a herbal composition of the invention as defined above and continuing such administration of the composition until said symptoms are reduced.
  • the present invention also provides the use of glucosamine and at least one herb selected from Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii in the manufacture of a medicament for the treatment of symptoms of an ailment which involves the inflammation or degeneration of joint tissues, such as arthritis.
  • a human or animal patient may thus be treated by a method which comprises the administration thereto of a pharmaceutical or veterinary composition of the invention as defined above.
  • the symptoms of arthritis and other joint ailments which involve inflammation and/or degeneration of joint tissues are thereby alleviated.
  • compositions enhance the synthesis of glucosaminoglycans and hyaluronic acid while reducing the inflammatory response, thereby promoting both the rebuilding and healing of affected joints.
  • Figure 1 provides a scheme which illustrates the cycle of tissue destruction and inflammation in osteoarthritis and how the components of the present formulation may modulate this cycle.
  • glucosamine can diminish tissue destruction;
  • Ligustrum lucidum can inhibit COX-2 enzyme activity;
  • Tripterygium wilfordii can inhibit the expression of COX-2 mRNA;
  • Erycibe schmidtii can inhibit inflammation and relieve pain.
  • the herbal compositions of the present invention may be used in dietary supplements and pharmaceutical or veterinary formulations.
  • the herb or herbs selected from Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii enhance the joint-rebuilding effect of the glucosamine without introducing any harmful side effects.
  • the herb(s) also provide an anti- inflammatory and analgesic effect.
  • the glucosamine used in the herbal composition of the present invention may be in any suitable form such as glucosamine sulphate, glucosamine hydrochloride or N-acetyl glucosamine. It may be employed as a dry powder or as a solution or dispersion. Preferably the glucosamine is a pharmaceutical grade that is commercially available,. An example of such a product is available from PharmLine, 41 Bridge Street, Florida, New York, 10921. Pharmaceutical grade glucosamine is standardized to greater than 97% purity.
  • the herbs used in the herbal composition of the present invention may be employed in any suitable form, for instance as dried herb or as a herbal extract.
  • the whole herb is typically dried and ground to a powder.
  • the resulting powder of the or each herb is then conveniently mixed with powdered glucosamine to form a herbal composition of the invention in powder form.
  • the powder can be administered directly, for instance by being dispersed in a liquid for human subjects to drink or by being mixed into animal feed for animals, for example cats, to consume.
  • the powder can be processed into any other conventional dosage form such as tablets, granules or capsules.
  • the extract is prepared by any conventional technique known for the extraction of ingredients from botanical material. Suitable techniques include solvent extraction and supercritical fluid extraction with a liquefied gas such as carbon dioxide. If desired the resulting extract may be dried before being formulated into a herbal composition of the invention, for instance by spray-drying or by freeze-drying (lyophilisation). In that case the dried extract may be mixed with powdered glucosamine to form a powder for direct administration to human or animal subjects, for instance as described above. Alternatively the extract may be used directly without prior drying. The herbs or herb extracts are combined with the glucosamine using any conventional technique that is suitable for ingredients of this type.
  • the herbs or herb extracts and the glucosamine are all in dry form they are conveniently mixed together, for instance by hand or by means of a mechanical mixer.
  • a mixing procedure of this type may also be suitable if some, but not all, of the components of the herbal composition are in dry form.
  • Tripterygium wilfordii extract When Tripterygium wilfordii extract is employed in extract form it is preferably a pharmaceutical grade extract that can be obtained commercially, for example, from the Institute of Medicinal Plant Development, Haiding District, Xibeiwang, Beijing 100094, China, a Chinese manufacturer. Pharmaceutical grade Tripterygium wilfordii extract manufactured in China is standardized for triptolide content of about 0.1 weight percent and contains the full spectrum of diterpenes found in the plant. The pharmaceutical grade extract must pass extensive safety and efficacy procedures. As employed in the practice of the invention, the extract has a minimum triptolide content of about 0.01 to 0.5 percent by weight. Preferably, the minimum triptolide content is about 0.1 percent by weight. It is thought that Tripterygium wilfordii acts by the mechanism depicted in Figure 1 to reduce the expression of cyclooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis.
  • COX-2 cycl
  • Ligustrum lucidum When Ligustrum lucidum is employed in extract form it is preferably a pharmaceutical grade extract that can be obtained commercially, for example, from the Institute of Medicinal Plant Development, Haiding District, Xibeiwang, Beijing 100094, China, a Chinese manufacturer.
  • the pharmaceutical grade extract must pass extensive safety and efficacy procedures.
  • Pharmaceutical grade Ligustrum lucidum extract manufactured in China is standardized for oleanolic acid content of about 45 percent by weight.
  • the Ligustrum lucidum extract used for the present invention preferably has an oleanolic acid content of about 30 to about 70 weight percent, and contains additional triterpenoids such as ursolic acid. More preferably, the extract used for the present compositions and methods has a minimum oleanolic acid content of about 45 percent by weight.
  • Ligustrum lucidum contains triterpenes oleanolic and ursolic acids which may provide the anti-inflammatory activity. Ligustrum lucidum can also provide hepatoprotection, antitumor promotion, antihyperlipidemia, antihyperglycemia, and protection against aspirin-induced ulcers.
  • Erycibe schmidtii is employed in extract form it is preferably a pharmaceutical grade extract that can be obtained commercially, for example, from the Institute of Medicinal Plant Development, Haiding District, Xibeiwang, Beijing 100094, China, a Chinese manufacturer.
  • the pharmaceutical grade extract must pass extensive safety and efficacy procedures.
  • Pharmaceutical grade Erycibe schmidtii extract manufactured in China is standardized for scopoletin content of about 0.35 weight percent.
  • the extract has a scopoletin content of about 0.25 to about 0.70 percentage by weight. More preferably the extract has a minimum scopoletin content of about 0.35 percent by weight.
  • Erycibe schmidtii (Ding Gon Teng) is the major ingredient herb (92% by weight) of the medicated wine called "Feng Liao Xing Feng Shi Die Da Yao Jiu" or "Ding Gong Teng Feng Shi Yao Jiu” (DGT wine).
  • the main chemical ingredients of E is the major ingredient herb (92% by weight) of the medicated wine called "Feng Liao Xing Feng Shi Die Da Yao Jiu" or "Ding Gong Teng Feng Shi Yao Jiu” (DGT wine).
  • the main chemical ingredients of E is the major ingredient herb (92% by weight)
  • schmidtii include scopoletin (the aglycone) and scopolin (the glycoside) which is thought to be responsible for the anti- inflammatory and analgesic activity of the herb.
  • the herbal composition of the present invention as described above is typically formulated into a pharmaceutical or veterinary composition or a dietary composition such as a dietary supplement, by a conventional method.
  • such compositions may include pharmaceutically, veterinarily or dietetically acceptable carriers or diluents as well as various additives such as other vitamins and minerals and inert ingredients such as talc and magnesium stearate that are standard excipients in the manufacture of tablets, capsules or other dosage forms.
  • the finished pharmaceutical or veterinary dosage form may be formulated for any route of administration such as orally, parenterally or topically.
  • the pharmaceutically, veterinarily or dietetically acceptable carrier or diluent may be, for example, a solvent, dispersion medium, coating, isotonic or absorption delaying agent, sweetener or the like.
  • the carrier may be prepared from a wide range of materials including, but not limited to, diluents, binders and adhesives, lubricants, disintegrants, coloring agents, bulking agents, flavoring agents, sweetening agents and miscellaneous materials such as buffers and adsorbents that may be needed in order to prepare a particular composition.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the present compositions is contemplated.
  • talc and magnesium stearate are included in the dietary compositions and/or pharmaceutical compositions of the present invention.
  • these components are preferably the Astac Brand 400 USP talc powder and the veritable grade of magnesium stearate.
  • Other ingredients to improve the manufacture of this composition as a dietary bar, functional food or pharmaceutical formulation include flavorings, sugars, proteins and/or modified starches, as well as fats and oils.
  • the dietary compositions and pharmaceutical and veterinary compositions of the present invention can be formulated into a finished dosage form in any suitable manner known to one of skill in the art.
  • the daily dosage takes account of factors such as the age, weight and condition of the patient to be treated.
  • a typical daily dosage is about 1500 mg of glucosamine for a human divided into one to three tablets, capsules or chewable bars.
  • the daily dose of glucosamine per kg of body weight is approximately 21 mg/kg-day.
  • the herbal composition of the invention for instance in the form of a dietary supplement or pharmaceutical composition, is formulated into a capsule or tablet using techniques available to one of skill in the art.
  • the recommended daily dose for an adult human or animal would preferably be one to six capsules or tablets.
  • the present compositions may also be formulated in any other convenient form, such as an injectable solution or suspension, a spray solution or suspension, a lotion, a gum, a lozenge, a food or snack item.
  • Food, snack, gum or lozenge items can include any ingestable ingredient, including sweeteners, flavorings, oils, starches, proteins, fruits or fruit extracts, vegetables or vegetable extracts, grains, animal fats or proteins.
  • the present herbal compositions can be formulated into food products such as cereals, snack items such as chips, bars, gum drops, chewable candies or slowly dissolving lozenges.
  • the herbal composition of the present invention is also suitably formulated into granules or a powder. In this form it can be readily dispersed in water or other liquid such as tea or a soft drink for human subjects to drink. It can be equally readily mixed into feed for administration to animals such as cattle, cats and dogs.
  • the herbal composition of the present invention is administered in an amount sufficient to relieve the symptoms of degenerative joint disease, joint inflammation or arthritis while minimizing adverse side effects.
  • a therapeutically effective amount is an amount sufficient to enhance the synthesis of glucosaminoglycans and hyaluronic acid without causing harmful side effects.
  • a therapeutically effective amount of the composition is an amount sufficient to reduce the expression or activity of cyclooxygenase-2 without causing harmful side effects. In yet another embodiment, the therapeutically effective amount is an amount sufficient to reduce the inflammatory response without causing harmful side effects.
  • a herbal composition of the present dietary invention is formulated to deliver each component in the following amounts: (a) about 15.0 to 25.0 mg glucosamine per kg body weight;
  • the herbal composition of the present invention is formulated to deliver each component in the following amounts: a. about 21 mg pharmaceutical grade glucosamine per kg body weight; b. about 1.5 mg Tripterygium wilfordii per kg body weight; c. about 5,0 mg Ligustrum lucidum per kg body weight; and d. about 6.5 mg Erycibe schmidtii per kg body weight.
  • a herbal composition of the invention was prepared containing pharmaceutical grade glucosamine, Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii.
  • the pharmaceutical grade glucosamine which is standardised to contain no less than 97% glucosamine calculated as glucosamine sulphate, was purchased from PharmLine, USA.
  • the three herb extracts were made at the Institute of Medicinal Plant Development, Beijing, China.
  • the authentication and quality evaluation of the raw herb material, critical to the production of the standardised herb extracts and the therapeutic effect of the finished product, were achieved by conventional macroscopic and microscopic methods of inspection and authentication involving the application of pharmacognosy, phytochemistry and Chinese Materia Medica. In addition TLC and HPLC profiling were used.
  • each extract contained a set amount of selected chemical markers which could be quantified by HPLC.
  • the chemical marker contents was 0.1% triptolide in Tripterygium wilfordii extract 45% oleanolic acid in Ligustrum lucidum extract and 0.35% scopoletin in Erycibe schmidtii extract.
  • Each extract was standardized.
  • the pharmaceutical grade glucosamine was combined with the herb extracts in a defined proportion of each ingredient of Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii to form a herbal composition.
  • a phamaceutical composition in tablet dosage form was prepared by formulating the herbal composition prepared according to Example 1 with such tabletting excipients as talc and magnesium stearate such that the following amounts of active ingredients could be delivered per kg body weight per day:
  • Example 2 In a clinical study on dogs, the tablet dosage form described in Example 2 was administered daily to a group of dogs (1 tablet per day) observed to be suffering from symptoms of arthritis. Preliminary observations by a veterinarian after a week to ten days indicated that there was an improvement in each animal's condition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une composition d'herbes médicinales contient une glucosamine ainsi qu'au moins une herbe médicinale chinoise choisie entre Tripterygium wilfordii, Ligustrum lucidum et Erycibe schmidtii. La composition d'herbe médicinale est utile pour soulager les symptômes d'une maladie caractérisée par l'inflammation ou la dégénérescence de tissus articulaires, telle que l'arthrite, et elle peut être formulée en un complément alimentaire ou une composition pharmaceutique ou vétérinaire.
EP00937014A 1999-06-02 2000-06-01 Combinaison de glucosamine avec des extraits d'herbes de tripterygium, ligustrum et erycibe Withdrawn EP1185281A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13717299P 1999-06-02 1999-06-02
US137172P 1999-06-02
US15397799P 1999-09-14 1999-09-14
US153977P 1999-09-14
PCT/GB2000/002092 WO2000074696A1 (fr) 1999-06-02 2000-06-01 Combinaison de glucosamine avec des extraits d'herbes de tripterygium, ligustrum et erycibe

Publications (1)

Publication Number Publication Date
EP1185281A1 true EP1185281A1 (fr) 2002-03-13

Family

ID=26834986

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00937014A Withdrawn EP1185281A1 (fr) 1999-06-02 2000-06-01 Combinaison de glucosamine avec des extraits d'herbes de tripterygium, ligustrum et erycibe

Country Status (6)

Country Link
EP (1) EP1185281A1 (fr)
AU (1) AU5231000A (fr)
CA (1) CA2376008A1 (fr)
GB (1) GB2367492A (fr)
MX (1) MXPA01012390A (fr)
WO (1) WO2000074696A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718198B2 (en) 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7270835B2 (en) 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
EP1687008B1 (fr) 2003-11-21 2024-04-17 Société des Produits Nestlé S.A. Composition alimentaire comprenant glucosamine
EP1890709B1 (fr) 2005-05-13 2011-11-09 Nestec S.A. Production de glucosamine végétal
EA013945B1 (ru) * 2005-05-13 2010-08-30 Нестек С.А. Способ получения обогащенного глюкозамином растительного сырья из различных видов растений
US20120263811A1 (en) * 2009-10-12 2012-10-18 Prashant Neminath Patil Herbal compositions improving lactation of farmed livestock
US8663623B2 (en) 2009-10-12 2014-03-04 Prashant Neminath Patil Herbal cattle feed supplement compositions for enhancing productivity and quality of milk
WO2011055387A2 (fr) * 2009-11-07 2011-05-12 Prashant Neminath Patil Compositions de remplacement du lait à base de plantes pour veaux
US8663719B2 (en) * 2009-11-23 2014-03-04 Prashant Neminath Patil Herbal calf starter compositions
WO2015067640A1 (fr) 2013-11-05 2015-05-14 Nestec S.A. Génération de glucosamine à partir de matières végétales
CN104096142A (zh) * 2014-07-16 2014-10-15 刘斌 一种治疗关节炎、关节疼痛的药物
CN105961117A (zh) * 2016-05-20 2016-09-28 芜湖欧标农业发展有限公司 一种欧洲彩叶女贞扦插繁殖方法
CN108567963B (zh) * 2018-06-26 2020-12-04 苏州科技城医院 一种治疗骨性关节炎的透骨草组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007066B1 (fr) * 1996-09-27 2005-11-16 The Board Of Regents, The University Of Texas System Procede de criblage pour des substances liant des recepteurs de glucocorticoide en utilisant des preparations de trypterygium wilfordii
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
AU7580098A (en) * 1997-05-15 1998-12-08 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
US6346280B1 (en) * 1997-05-15 2002-02-12 University Of Washington Composition and methods for inhibiting the formation of brain amyloid deposits
US6264994B1 (en) * 1997-05-15 2001-07-24 University Of Washington Compositions for treating alzheimer's disease and other amyloidoses
US5972998A (en) * 1997-05-23 1999-10-26 Hoechst Marion Roussel, Inc. Triptolide derivatives useful in the treatment of autoimmune diseases
CN102274272A (zh) * 1998-05-19 2011-12-14 研究发展基金会 三萜组合物和它们的使用方法
US6150539A (en) * 1998-09-02 2000-11-21 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0074696A1 *

Also Published As

Publication number Publication date
CA2376008A1 (fr) 2000-12-14
MXPA01012390A (es) 2003-10-14
GB2367492A (en) 2002-04-10
AU5231000A (en) 2000-12-28
WO2000074696A1 (fr) 2000-12-14
GB0131054D0 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
US20230017195A1 (en) Compositions and methods of treating viral infections
AU2006232644B2 (en) Anti-inflammatory formulation
WO2000074696A1 (fr) Combinaison de glucosamine avec des extraits d'herbes de tripterygium, ligustrum et erycibe
EP2224939B1 (fr) Préparation avec des extraits de cynorhodon, et procédé de fabrication d'extraits de cynorhodon
US9144577B2 (en) NGNA compositions and methods of use
US20190015448A1 (en) Treatment and Prevention of Bone and Joint Disorders
WO2008034316A1 (fr) Préparation de composés capable de reduction rapide de stress oxidatif et son procédé de préparation
EP2247290A1 (fr) Polyphénols destinés au traitement des troubles du cartilage
EP1609466B1 (fr) Composition pharmaceutique et sa utilisation pour la mise en oeuvre d'un medicament pour le traitement du surpoids et/ou des symptomes correles dans le corps humain et animal et son procede de production.
Brendler et al. Devil’s Claw (Harpagophytum procumbens DC) an evidence-based systematic review by the natural standard research collaboration
US11039636B2 (en) Treatment and prevention of bone and joint disorders
EP1677627B1 (fr) Preparation dietetique contenant un hyaluronate pour le traitement de l'osteoporose
AU5231200A (en) Formulations containing cranberry fruit, dl-methionine, and chinese herbs
KR20090027383A (ko) 고지혈증의 예방 또는 치료용 조성물
AU2022203588A1 (en) Composition and methods and uses thereof
WO2023150113A1 (fr) Composition de santé articulaire à action rapide et son utilisation
Wynn Ten herbs and nutraceuticals you can't live without.
CN117883520A (zh) 人参桑黄二氢槲皮素
JP2020147514A (ja) 胆汁酸と生薬を含有する組成物
JP2022022617A (ja) 筋肉合成能促進剤
JPH1129488A (ja) ピコスルファートナトリウムを含有する医薬組成物
Jamison Nutraceuticals for Osteoarthritis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20020510

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040103